logo-loader
viewAcelRx Pharmaceuticals

AcelRx Pharmaceuticals takes a chill pill; reports Q2 loss, misses revenue estimates

In the second quarter of 2018, AcelRx reported a net loss of US$10.5 million, compared to US$13.1 million for the second quarter of 2017.

1533246361_microscope.jpg
The specialty pharma company develops under-the-tongue therapies for acute pain

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) released its second-quarter results Thursday, missing estimates and reporting a loss of US$10.5 million. 

The drugmaker, which develops under-the-tongue therapies for acute pain, posted revenue of US$818,000 in the period. 

In the second quarter of 2018, its net loss was US$10.5 million, or US$0.20 per basic and diluted share, compared to US$13.1 million, or US$0.29 per basic and diluted share, for the second quarter of 2017.

READ: AcelRx Pharmaceuticals receives European regulatory approval for its opioid pain killer DZUVEO

In after-hours trading, shares of the California-based company were down 1.9% at US$2.60.

"The first half of the year has been productive on all fronts as we have accomplished all the milestones we established for the period. We're very focused on reaching our remaining milestones for the year and, if DSUVIA is approved in November, eager to start commercializing our first U.S. product in Q1 2019," said chief executive Vince Angotti in a statement. 

"We continue to believe we have a unique product for the management of moderate to severe acute pain that can fulfill an unmet need within appropriate healthcare settings. We look forward to continued dialogue with the FDA during the coming months to achieve these objectives."

In May, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for DSUVIA in May. The company also received approval from the European Commission for DZUVEO for the management of acute moderate-to-severe pain in medically monitored settings.

 

Quick facts: AcelRx Pharmaceuticals

Price: 1.6 USD

NASDAQ:ACRX
Market: NASDAQ
Market Cap: $127.32 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Xpediator's Stephen Blyth outlines five-year growth plans as core businesses...

Xpediator PLC's (LON:XPD) Stephen Blyth speaks to Proactive London following the release of its 2019 trading update. The firm saw turnover rise 19% to £212mln - boosted by acquisitions and organic growth while adjusted pre-tax profit's expected to be slightly above £5mln. Blyth says a big...

2 days, 16 hours ago

2 min read